Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Corona Virus Disease 2019 (COVID-19) is a new illness caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms are variable but typically include fever, cough, respiratory symptoms, diarrhea, reduction of smell and taste sensation. Severity ranges from mild to severe and the virus may lead to pneumonia, acute respiratory distress syndrome and death, in some patients. Nearly every country in the world has been affected by this virus and is currently defined as a pandemic, by the World Health Organization.

Source: Journal of the Neurological Sciences - March 24, 2020 Category: Neurology Authors: International MG/COVID Working Group, S. Jacob, S. Muppidi, A. Guidon, J. Guptill, M. Hehir, J.F. Howard, I. Illa, R. Mantegazza, H. Murai, K. Utsugisawa, J. Vissing, H. Wiendl, R.J. Nowak Tags: Clinical short communication Source Type: research